Equities Analysts Set Expectations for NAGE Q1 Earnings

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Investment analysts at HC Wainwright raised their Q1 2026 EPS estimates for Niagen Bioscience in a report issued on Thursday, March 5th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.08 per share for the quarter, up from their previous forecast of $0.05. HC Wainwright also issued estimates for Niagen Bioscience’s Q2 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.12 EPS, FY2026 earnings at $0.33 EPS, Q1 2027 earnings at $0.07 EPS, Q2 2027 earnings at $0.09 EPS, Q3 2027 earnings at $0.10 EPS, Q4 2027 earnings at $0.11 EPS and FY2027 earnings at $0.37 EPS.

Several other equities analysts have also recently issued reports on NAGE. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd. Canaccord Genuity Group cut their price objective on Niagen Bioscience from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Niagen Bioscience Trading Down 0.8%

Shares of NASDAQ NAGE opened at $5.06 on Friday. The firm has a fifty day simple moving average of $5.74 and a two-hundred day simple moving average of $7.14. Niagen Bioscience has a 12 month low of $4.72 and a 12 month high of $14.69. The firm has a market capitalization of $405.20 million, a PE ratio of 25.30 and a beta of 2.11.

Hedge Funds Weigh In On Niagen Bioscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. purchased a new stake in shares of Niagen Bioscience in the 3rd quarter worth about $37,522,000. Arrowstreet Capital Limited Partnership purchased a new position in Niagen Bioscience during the 3rd quarter valued at about $13,405,000. UBS Group AG bought a new stake in Niagen Bioscience during the third quarter worth about $11,160,000. Qube Research & Technologies Ltd bought a new stake in Niagen Bioscience during the third quarter worth about $8,175,000. Finally, Millennium Management LLC purchased a new stake in Niagen Bioscience in the third quarter worth about $7,224,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Trending Headlines about Niagen Bioscience

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Q4 beat and profit strength — Niagen reported quarterly EPS that topped estimates and stronger-than-expected revenue; media coverage notes the company doubled annual profit and management signaled an acquisition hunt and expansion into GLP‑1-style products, which drove significant after-hours buying interest. Niagen Bioscience Doubles Annual Profit (MSN)
• Positive Sentiment: Quarterly beat confirmed by multiple outlets — Coverage and transcripts highlight strong revenue growth and an EPS beat for Q4, supporting the narrative of improving operations and profitability. NAGE Tops Q4 Earnings (Zacks)
• Neutral Sentiment: Price target tweak but rating intact — Canaccord trimmed its price target from $14 to $13 while maintaining a “buy” rating, signaling continued analyst conviction but a more conservative valuation. Canaccord Price Target Update (Benzinga)
• Neutral Sentiment: HC Wainwright updated multi-quarter and FY2027 EPS models — the firm published a full set of quarterly and FY2027 estimates (FY2027 ~$0.37 EPS), providing a new baseline for investor expectations (mixed across quarters).
• Negative Sentiment: Revenue guidance below street estimates — Niagen issued FY2026 revenue guidance of $142.4M–$148.8M versus a consensus around $153.3M, which reduces near-term top-line visibility and likely pressured the share price despite the quarterly beat. Valuation After New 2026 Guidance (Yahoo)
• Negative Sentiment: Analyst cuts to FY2026 and near-term quarters — HC Wainwright reduced FY2026 EPS (from $0.38 to $0.33) and cut Q2 2026 materially, which may weigh on sentiment as models are reset lower despite stronger Q4 results.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.